Comparing short vs long radiation with immunotherapy for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rectal adenocarcinoma confirmed by biopsy.
- The tumor must be at a stage where it has grown into or through the rectal wall or spread to nearby lymph nodes but not to distant organs.
- The tumor must be within 10 cm of the anal verge.
- Your cancer must be microsatellite stable (MSS).
- You cannot have had any prior cancer treatment for this rectal cancer.
- You must be in good overall health with adequate organ function.
- You cannot have an active autoimmune disease or be on strong immunosuppressants.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a new approach for locally advanced rectal cancer. You'll receive a short course of radiation, then chemotherapy plus an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination shrinks the tumor enough to avoid surgery or improve outcomes.
This trial tests a shorter course of radiation therapy that avoids lymph nodes, followed by an immunotherapy drug, for patients with stage II or III rectal cancer that has not spread. It aims to improve outcomes while reducing side effects.
This trial tests a shorter course of radiation before chemotherapy and an immunotherapy drug to shrink mid-to-lower rectal cancer that has not spread. The goal is to improve treatment response and reduce side effects, potentially allowing for less invasive surgery.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.